alfentanil

Trade name: alfenta

Small moleculeapproved

Approved

Dec 29, 1986

Alfentanil is an opioid analgesic with a rapid onset of action. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Alfentanil, marketed under the trade name Alfenta, Rapifen in Australia is indicated for the management of postoperative pain and the maintenance of general anesthesia. — NCATS

Clinical trial activity

38 trials · 49 clinical orgs · 3 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
3
Phase 4
14

Earliest trial started Aug 1, 1997 (NCT00226564)

Timeline

1980s

  1. Dec 29, 1986

    Akorn, Inc. — Earliest FDA Approval

  2. Dec 29, 1986

    Akorn, Inc. — NDA Secondary Org

  3. Dec 29, 1986

    Akorn, Inc. — NDA Organization

  4. Dec 29, 1986

    Rising Pharmaceuticals — Marketing Organization

1990s

  1. Oct 28, 1999

    Hospira — Marketing Organization

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 29, 1986

Chemistry & pharmacology

Loading structure…

SMILES

CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1
Mol. weight
416.53 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • afentanyl
  • alfenta
  • alfenta
  • alfenta
  • alfentanil
  • alfentanil
  • alfentanil
  • alfentanil
  • alfentanil
  • alfentanil
  • alfentanil
  • alfentanil
  • alfentanil
  • alfentanil hcl
  • alfentanil hcl
  • alfentanil hcl
  • alfentanil hydrochloride
  • alfentanil hydrochloride
  • alfentanil hydrochloride
  • alfentanil hydrochloride
  • alfentanil hydrochloride
  • alfentanilum
  • alfentanilum
  • alfentanyl
  • alfentanyl
  • alfentanyl
  • lfentanil hydrochloride
  • n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide
  • n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide
  • r-39209
  • r-39209
  • rapifen
  • rapifen
  • rapifen
  • rapifen conc
  • rapifen dilute
  • rapifen intensive care

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07211828N/AOct 10, 2025China Medical University, National Yang Ming Chiao Tung University Hospital
NCT06563297Phase 4Aug 13, 2024Kaohsiung Medical University
NCT06414018N/AMay 20, 2024Henan Medical University, Huazhong University of Science and Technology
NCT05688384Phase 4Jan 19, 2023Government of Sweden, Region Östergötland
NCT04658173N/ADec 22, 2020Tianjin University of Traditional Chinese Medicine
NCT03359395Phase 4Jun 4, 2018Wake Forest University
NCT02838056N/AFeb 21, 2017Taipei Medical University
NCT02625181N/AJul 1, 2016University of Washington, Vanderbilt University
NCT02646592N/AApr 1, 2016APHP - Hôpital Necker, University of Paris
NCT02725723Phase 2/Phase 3 (Phase 3)Mar 1, 2016Tel Aviv University
NCT02358057Phase 4Feb 1, 2015Université catholique de Louvain
NCT02267681Phase 4Oct 1, 2014Ufuk University
NCT02000206N/AFeb 1, 2014Tel Aviv University
NCT04196946N/ASep 2, 2013Nigde Omer Halisdemir University
NCT01805726Phase 3Feb 1, 2013Saint-Joseph University
NCT02486926N/ANov 1, 2012Hallym University
NCT02022488Phase 4Feb 1, 2012Yeditepe University
NCT01550354N/AFeb 1, 2012Yonsei University
NCT01436799N/AMar 1, 2011Gachon University
NCT01371968N/AFeb 1, 2011Malaysian Society of Anaesthesiologists, University of Malaya
Showing 20 of 38 trials
Page 1 / 2

Organizations

Research & Development (49)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tel Aviv UniversityAcademic/Hospital3322010
Hennepin HealthcareAcademic/Hospital2212009
Stanford UniversityAcademic/Hospital2212008
APHP - Hôpital NeckerAcademic/Hospital1112016
Brazilian Society of Thoracic SurgeryAcademic/Hospital1012007
CareFusionFor profit1012002
Chang Gung UniversityAcademic/Hospital1112010
China Medical UniversityAcademic/Hospital1112025
Gachon UniversityAcademic/Hospital1112011
German Federal Ministry of Education and ResearchGovernment1012002
Ghent UniversityAcademic/Hospital1112008
Gloucestershire Hospitals NHS Foundation TrustAcademic/Hospital1112010
Government of SwedenGovernment1112023
Hallym UniversityAcademic/Hospital1112012
Hebrew UniversityAcademic/Hospital1111997
Henan Medical UniversityAcademic/Hospital1012024
Hospital PompeiaAcademic/Hospital1112007
Huazhong University of Science and TechnologyAcademic/Hospital1112024
Johns Hopkins UniversityAcademic/Hospital1112009
Kaohsiung Medical UniversityAcademic/Hospital1112024
49 organizations
Page 1 / 3

Marketing (4)

OrganizationOrg typeRelationshipDate
Akorn, Inc.For profitNDA2Dec 29, 1986
Akorn, Inc.For profitNDADec 29, 1986
HospiraFor profitMKTGOct 28, 1999
Rising PharmaceuticalsFor profitMKTGDec 29, 1986